ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery Incubator Award.

The Immunomic Therapeutics’ Cancer Discovery Incubator offers the selected innovator the opportunity to develop a proof-of-concept experiment in their laboratories. Additionally, the winner will be awarded funding, lab equipment and a unique mentorship with the Immunomic executive team for one year.

“In time, Immunomic found success, but if it wasn’t for the help of a similar incubator opportunity, we might not be where we are today,” said Dr. William Hearl, CEO of Immunomic Therapeutics. “It is exciting to pay it forward and empower a new innovator to work in Maryland and conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.”

The application period will be open until December 31, 2016 and the winner will be announced in February of 2017.

“It is wonderful to see successful Maryland biotechnology companies lend a hand to new innovators,” stated Rich Bendis, President and CEO of BioHealth Innovation, Inc. “We are thrilled to be a partner for the Immunomic Therapeutics incubator as it is an excellent example of how the Maryland life sciences community diligently works together to support success and growth throughout the scientific community.”

For more information about the Immunomic Therapeutics’ Cancer Discovery Incubator please visit

About ITI

Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology works with the body’s natural biochemistry system and has the potential to improve a broad range of vaccines. ITI entered into a licensing agreement with Astellas Pharma Inc. in 2015 to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases, and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit

After experiencing partnering success and a $315 million deal with Japan-based Astellas Pharma Inc. for their LAMP-Vax platform technology in allergy, Immunomic Therapeutics, in concert with BioHealth Innovation, is giving back to the region’s growing scientific community with the Cancer Discovery Incubator Award. The incubator will enable and accelerate beginning ventures aimed at offering measurable change in oncological health.


Immunomic Therapeutics
Sia Anagnostou, 717-327-1822